Antioxidants in the prevention of atherosclerosis

Current Opinion in Lipidology

Volumn 7, Issue 6, 1996, Pages 374-380

  Olsson, Anders G ^a   Yuan, Xi Ming ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; PROBUCOL;

ANTIOXIDANT ACTIVITY; ATHEROMA; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; REVIEW;

ANIMALIA;

EID: 0030499594     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199612000-00006     Document Type: Review

References (45)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: modifications of LDL that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
2. Alpha-Tocopherol Beta-Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330:1029-1035.
3. Blot W, Li J, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY et al.: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993, 85:1483-1492.
4. Stephens N, Parsons A, Schofield P, Kelly F, Cheeseman K, Mitchinson MJ: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Oxidation Study (CHAOS). Lancet 1996, 347:781-786. The effect of vitamin E (400 or 800 IU daily) was studied in 2002 patients with CHD. Treatment reduced the primary trial endpoint of cardiovascular death and non-fatal myocardial infarction from 64 in the placebo group to 41 in the vitamin E group (P=0.005). A nonsignificant excess of cardiovascular deaths was observed in the vitamin E group. This is the first prospective clinical trial with results consistent with the lipid oxidation hypothesis of CHD.
5. Reaven P, Khouw A, Beltz W, Parthasarathy S, Witztum J: Effects of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene. Arterioscler Thromb 1993, 13:590-600.
6. Walldius G, Erikson U, Olsson A, Bergstrand L, Hådell K, Johansson J, Kaijser L, Lassvik C, Mölgaard J, Nilsson S: The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial. Am J Cardiol 1994, 74:875-883.
7. Yamamoto A, Matsuzawa Y, Kishino B, Hayashi R, Hirobe K, Kikkawa T: Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis 1983, 48:157-166.
8. Yamamoto A, Matsuzawa Y, Yukoyama S, Funahashi T, Yamamura T, Kishino B: Effects of probucol on xanthoma regression in familial hypercholesterolemia. Am J Cardiol 1986, 57(suppl):29H-35H.
9. ••] was more resistant to oxidation as determined by the lag phase for conjugated dienes, showed much lower formation of lipid peroxides, reduced macrophage LDL degradation and less decrease in receptor binding, indicating that probucol has antioxidant effects on LDL.
10. Elinder LS, Walldius G: Simultaneous measurement of serum probucol and lipid-soluble antioxidants. J Lipid Res 1992, 33:131-137.
11. 2b correlated highly significantly with femoral lumen volume change and could, therefore, partly explain the negative finding in PQRST.
12. Schäfer-Elinder L, Hådell K, Johansson J, Mölgaard J, Holme I, Olsson AG, Walldius G: Probucol treatment decreases serum concentrations of diet-derived antioxidants. Arterioscler Thromb Vasc Biol 1995, 15:1057-1063. Probucol given to patients in the PQRST reduced serum vitamin E concentrations by 14%, secondary to cholesterol and triglyceride lowering, and reduced carotenoids by 30-40% because of reductions in lipoprotein particle size and competition for incorporation into VLDL. The use of a lipid-soluble antioxidant and cholesterol lowering drug might have unfavourable effects on blood levels of diet-derived antioxidants.
13. Johansson J, Carlson L, Landou C, Hamsten A: High density lipoproteins and coronary atherosclerosis: a strong relation with the largest HDL particles, that is confined to normotriglyceridemic subjects. Arteriosclerosis 1991, 11:174-184.
14. Wilson H, Patel J, Skinner E: The distribution of high density lipoproteins in coronary survivors. Biochem Soc Trans 1991, 18:1175-1176.
15. Jialal I, Norkus E, Cristol L, Grundy S: Beta-carotene inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1991, 1086:134-138.
16. Princen H, Poppel G, Vogelezang C, Buytenhek R, Kok F: Supplementation with vitamin E but not beta-carotene in vivo protects low density lipoproteins from lipid peroxidation in vitro. Arterioscler Thromb 1992, 12:554-562.
17. Shaish A, Daugherty A, O'Sullivan F, Schonfeld G, Heinecke J: Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J Clin Invest 1995, 96:2075-2082.
18. Gaziano J, Manson J, Ridker P, Buring J, Hennekens C: Beta carotene therapy for chronic stable angina [Letter]. Circulation 1990, 82(Suppl III):202.
19. Hennekens C, Buring J, Manson J, Stampfer M, Rosner B, Cook NR, Belanger C, La Motte F, Gaziano JM, Ridker PM et al.: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996, 334:1145-1149. Beta-carotene was administered to 11036 male physicians at 50 mg on alternate days for 12 years; the effect on cancer and cardiovascular disease was compared in a randomized double blind study with 11035 men receiving placebo. No early or late differences were found in the overall incidence or mortality of malignant neoplasms or cardiovascular disease.
20. Omenn G, Goodman G, Thornquist M, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH et al.: Effects of combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334:1150-1155. More than 18000 individuals at risk for lung cancer were treated with a supplement of 30mg beta-carotene and 25000 IU of retinol for four years; the relative risk of death from cardiovascular disease after the trial was 1.26. The combined treatment might have adverse effect on the risk of death from lung cancer and cardiovascular disease.
21. The Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with cornary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
22. Princen HMG, Poppel GV, Vogelezang C, Buytenhek R, Kok FJ: Supplementation with vitamin E but not β-carotene in vivo protects LDL from lipid peroxidation in vitro: effect of cigarette smoking. Arterioscler Thromb 1992, 12:554-562.
23. Jialal I, Fuller C, Huet B: The effect of α-tocopherol supplementation on LDL oxidation. A dose-response study. Arterioscler Thromb Vasc Biol 1995, 15:190-198. In a randomized placebo-controlled dose response study of the effect of α-tocopherol LDL oxidation over 8 weeks it was found that the minimum dose of 400 IU effectively inhibited oxidation.
24. Steinberg D: Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? Lancet 1995, 346:36-38.
25. Ball R, Stowers E, Burton J, Cary R, Skeeper J, Mitchinson M: Evidence that the macrophage foam cell contributes to the lipid core of atheroma. Atherosclerosis 1995, 114:45-54.
26. Devaraj S, Li D, Jialal I: The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1β secretion, and monocyte adhesion to endothelium. J Clin Invest 1996, 98:756-763. The effect of α-tocopherol supplementation on monocyte function relevant to atherogenesis was studied in 21 healthy individuals. Supplementation decreased the release of reactive oxygen species, lipid oxidation, interleukin-1β secretion and monocyte-endothelial cell adhesion. The study provided evidence for an intracellular antiatherogenetic effect of α-tocopherol in monocytes.
27. Sullivan J: Iron and the sex difference in heart disease risk. Lancet 1981, i:1293-1294.
28. Morrison H, Semencin R, Mao Y, Wigle D: Serum iron and risk of fatal acute myocardial infarction. Epidemiology 1994, 5:243-246.
29. Ascherio A, Willet W, Rimm E, Giovanucci E, Stampfer M: Dietary iron intake and risk of coronary disease among men. Circulation 1994, 89:969-974.
30. Sempos C, Looker A, Gillum R, Maskuc D: Body iron stores and the risk of coronary heart disease. N Engl J Med 1994, 330:1119-1124.
31. Swain J, Gutteridge J: Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett 1995, 368:513-515.
32. Hazell L, Arnold L, Flowers D, Waeg G, Malle E, Stocker R: Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996, 97:1535-1544.
33. Yuan XM, Li W, Olsson AG, Brunk UT: Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis 1996, 124:61-73. Iron and ferritin loaded macrophages were demonstrated in human atherosclerotic lesions. Human macrophages have a capacity to take up iron by phagocytosing iron-containing structures, then release the iron into the environment, contributing to LDL oxidation.
34. Lamb D, Mitchinson M, Leak D: Transition metal ions within human atherosclerotic lesions can catalyse the oxidation of low density lipoprotein by macrophages. FEBS Lett 1995, 374:12-16. Iron from human atheromas catalysed the macrophage-mediated LDL oxidation. This is inhibited by pretreatment of the atheroma gruel with Chelex-100.
35. Evans P, Smith C, Mitchinson M, Halliwell B: Metal ion release from mechanically-disrupted human arterial wall. Implications for the development of atherosclerosis. Free Radical Res 1995, 23:465-474.
36. Paganga G, Rice-Evans C, Rule R, Leake D: The interaction between ruptured erythrocytes and low-density lipoproteins. FEBS Lett 1992, 303:154-158.
37. Miller Y, Felikman Y, Shaklai N: Hemoglobin induced apolipoprotein B crosslinking in low-density lipoprotein peroxidation. Arch Biochem Biophys 1996, 326:252-260.
38. Jacob H: Newly recognised causes of atherosclerosis: the role of microorganisms and of vascular iron overload. J Lab Clin Med 1994, 123:808-824.
39. Araujo J, Romano E, Brito B, Parthé V, Romano M, Bracho M, Montano RF, Cardier J: Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler Thromb Vasc Biol 1995, 15:1172-1180.
40. Lenten B, Prieve J, Navab M, Hama S, Lusis A, Fogelman A: Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest 1995, 95:2104-2110. The causes of resistance to atherosclerosis in some mouse strains may be higher levels of liver apoferritin and lower concentrations of free iron. This paper provided the first evidence demonstrating that liver peroxidation may be an important variable in intracellular iron homeostasis.
41. Pang J, Jiang M, Chen Y, Wang FW, Wang DL, Chu SH, Chau LY: Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest 1996, 97:2204-2212. The authors studied iron metabolism and atherogenesis at molecular and cellular levels, in animal models and human lesions. Increased ferritin gene expression and ferritin loading in macrophages and smooth muscle cells with human atheromas were demonstrated.
42. Juckett M, Balla J, Balla G, Jessurun J, Jacob H, Vercellotti G: Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. Am J Pathol 1995, 47:782-789. This study provides in-vttro and in-vivo evidence that ferritin might protect endothelial cells from oxidative injury in atherosclerosis.
43. Angelucci D, Napolitano A, Mezzetti A, Cuccurullo F: Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994, 14:299-304.
44. Belcher J, Balla J, Balla G, Jacobs DR, Gross JM, Jacob HS, Vercellotti GM: Vitamin E, LDL, and endothelium. Brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro. Arterioscler Thromb 1993, 13:1779-1789.
45. Salonen J, Korpela H, Nyyssönen K, Porkkala E, Tuomainen T-P, Belcher JD, Jacobs DR, Salonen R: Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins: a randomized cross-over trial in male smokers. J Intern Med 1995, 237:161-168. The role of iron in atherogenesis was studied in a clinical trial. The authors showed that reduction of body iron stores by venesection increases the oxidative resistance of LDL in smokers.